CEL-SCI Corporation
(NYSE Amex Equities : CVM)

( )
CVM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading CVM News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.31%72.131.0%$655.07m
AMGNAmgen Inc.
0.63%155.770.8%$509.15m
CELGCelgene Corporation
0.24%115.221.0%$465.18m
ARIAARIAD Pharmaceuticals, Inc.
0.23%23.7016.4%$416.43m
BIIBBiogen Inc.
0.21%283.611.0%$405.76m
ALXNAlexion Pharmaceuticals, Inc.
0.42%135.872.5%$385.05m
REGNRegeneron Pharmaceuticals, Inc.
-0.08%362.952.5%$365.07m
ILMNIllumina, Inc.
0.47%161.233.8%$225.12m
CLVSClovis Oncology, Inc.
0.64%56.6217.9%$166.73m
VRTXVertex Pharmaceuticals Incorporated
1.19%82.522.1%$152.50m
INCYIncyte Corporation
1.28%115.092.2%$149.42m
SRPTSarepta Therapeutics, Inc.
-0.42%35.9816.8%$110.90m
ACADACADIA Pharmaceuticals Inc.
3.06%32.3118.3%$110.16m
IONSIonis Pharmaceuticals, Inc.
1.12%47.148.9%$110.11m
TSROTESARO, Inc.
-1.32%149.2615.0%$109.40m

Company Profile

CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against advanced primary head and neck cancer. It is also developing its pre-clinical Ligand Epitope Antigen Presentation System technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis. CEL-SCI was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.